Benzinga | Sep 15, 2020 08:20AM EDT

Chardan Capital Maintains Buy on 89bio, Raises Price Target to $95

Chardan Capital analyst Michael Morabito maintains 89bio (NASDAQ:ETNB) with a Buy and raises the price target from $59 to $95.Chardan Capital analyst Michael Morabito maintains 89bio (NASDAQ:ETNB) with a Buy and raises the price target from $59 to $95.